

Biocon Biologics Limited

CIN: U24119KA2016PLC093936
Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN
T +91 080-6775 6775, **F** +91 080-6775 1030
E contact@bioconbiologics.com
www.bioconbiologics.com

November 27, 2025

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01
SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Company Statement

Please find enclosed the company statement titled “**Biocon Biologics’ Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)**”.

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh Nand

Company Secretary

Membership No. ACS 13669

Address: Biocon House, Semicon Park
Tower 3, Electronic City Phase 2, Hosur Road
Bengaluru, Karnataka

Encl: as above

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Biologics' Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)

Bengaluru, Karnataka, India, November 27, 2025

“The U.S. Food and Drug Administration (FDA) CDER-OC, Office of Manufacturing Quality, has classified Biocon Biologics' Drug Substance Facility at Biocon Campus, located in Bengaluru, Karnataka, as Voluntary Action Indicated (VAI).

This relates to the inspection conducted by the agency between August 26 to September 3, 2025, and pertains to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States.

Biocon Biologics remains committed to global standards of Quality and Compliance.”

– Company Spokesperson